Moderna vaccine protects against COVID-19 in Nonhuman Primat
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The mRNA vaccine co-developed by Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) protected both the upper and lower airways of non-human primates against SARS-CoV-2 infection, according to results published in NEJM journal.


~ Nonhuman primates received 10 or 100 ?g of the mRNA-1273 vaccine.

~ Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2.

~ Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by a polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens.


~ Candidate induced antibody levels exceeding those in human convalescent-phase serum.

~ Induced type 1 helper T-cell (Th1)–biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses.

~ Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups.

~ No viral replication was detectable in the nose of any of the 8 animals in the 100-?g dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group.


Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung.

Moderna announced on 27 July that it had begun dosing in a phase III trial, expected to comprise 30,000 individuals with half receiving the vaccine and half receiving placebo. Read more:

Dr. T●●●●z H●●●●●●i and 1 others like this